Insights & News

The GBUK group - which comprises trading entities GBUK Ltd and GBUK Enteral Ltd - has secured significant platform investment from H2 Equity Partners (H2), a UK and Netherlands based mid-market Private Equity firm. The shareholders of GBUK were advised by leading M&A specialist BCMS.

Established in 2008, GBUK is an award-winning distributor of own brand and third party medical consumables, supplying products including suction liners, catheters and enteral feeding products.
The group has developed longstanding and embedded relationships with a large number of NHS departments, and is named on a number of NHS framework agreements. GBUK delivers to the majority of NHS hospitals in the UK, including all 657 acute hospitals. An estimated 215,000 GBUK products are used daily.

Primed for growth

With platform investment from H2, the GBUK group has outlined ambitious expansion plans, including becoming a market leading specialist healthcare group over the coming years.

Founded in 1991, H2 is a leading investment firm with offices in London and Amsterdam. The organisation has an established reputation for an active, ‘hands-on’ approach that supports and develops growth to build better businesses. H2 also has significant prior experience in the healthcare sector.

Guy Mills of GBUK said: “I’m delighted to have found a strong investor who is keen to support the current management team to continue growth with an independent and entrepreneurial spirit. GBUK group together with H2’s knowledge and support now have the opportunity to take full advantage of new opportunities within the UK market and abroad.”

Hugh Ashburner, Associate Director of BCMS’ Major Transactions Group, said: “Investment activity in the healthcare sector is currently strong, and there was significant interest in GBUK from a number of sources. For GBUK, Private Equity was clearly the preferred route, as this deal allows the group to remain independent and build market share.

“This successful deal is testament to the ambition and commitment to excellence of both parties. With added investment and strategic direction, GBUK can grow to be the market leader in its core product areas, as well as take advantage of other strategic growth opportunities.”